Solid Biosciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Solid Biosciences Inc
Access all reports
Solid Biosciences Inc. is a life science company dedicated to developing therapies for neuromuscular and cardiac diseases. The company's primary focus includes advancing a portfolio of gene therapy candidates for various conditions, such as Duchenne muscular dystrophy with its lead product candidate SGT-003, Friedreich's ataxia treated by AVB-202-TT, and BAG3-mediated dilated cardiomyopathy with AVB-401. Solid Biosciences is also working on developing platform technologies that include dual gene expression, allowing for the packaging of multiple transgenes into one vector, and the exploration of novel capsids. The company's mission is driven by a commitment to improve the daily lives of patients living with these debilitating diseases, supported by collaborations and partnerships, including a notable agreement with Ultragenyx Pharmaceutical Inc. for the development and commercialization of new gene therapies for Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
Ticker symbol
Country
đșđž United States